此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

通过基于神经可塑性的计算机化训练利用乙酰胆碱改善轻度认知障碍患者的神经健康 (INHANCE-MCI)

2026年9月17日 更新者:Posit Science Corporation

通过基于神经可塑性的计算机化训练改善轻度认知障碍患者神经健康(INHANCE-MCI)

This study is a validation study to evaluate efficacy of two neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment (MCI).

研究概览

详细说明

The primary objective of this study is to evaluate will evaluate the impact of speed training to change cholinergic signaling, cognitive performance, and functional abilities in patients with MCI, as evidenced by [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET) and standard measures of cognition and function.

The investigators will employ a prospective, double-blind, parallel-arm, active-controlled, randomized clinical trial in patients with clinically-defined mild cognitive impairment aged 65 and above with a baseline MoCA of 18-26 inclusive.

Approximately 84 participants will be consented to ensure the successful completion of at least 70 participants (post 20% attrition). Participants will then complete the Screening (V0) assessments to determine eligibility. Following inclusion, participants will complete the Baseline (V1) assessments, PET imaging and structural MRI scan; participants will then be randomized into either the speed-based brain training or an active control of visual non-speeded computerized games and will engage in approximately 35 hours of program use for the 10-week Intervention Period. Following the 10-week intervention, participants will complete a Post-Intervention (V2) assessment, and PET imaging to evaluate changes in cognitive function. Participants will then stop using their assigned program for 3 months and return for a Follow-up (V3) end-of-study assessment and PET imaging to evaluate the endurance of changes in cognition, function, and behavior in the absence of further program use.

研究类型

介入性

注册 (估计的)

84

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Quebec
      • Montreal、Quebec、加拿大、H3A 2B4
        • 招聘中
        • Montreal Neurological Institute-Hospital
        • 首席研究员:
          • Etienne de Villers-Sidani, PhD
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 及以上 (年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Potential participant must be 65 years or older at the time of study screening.

  2. Potential participant must have MCI as defined by:

    • Total score between 18-26 inclusive on the Montreal Cognitive Assessment (MoCA)
    • Cognitive concern by participant, informant, or clinician and evidence of preserved functional abilities as defined as a Clinical Dementia Rating (CDR) of 0.5 with a memory score of 0.5 or 1.
  3. Potential participant must have a study partner/informant defined as any acquaintance (e.g., family member, friend, neighbor, clinician) who has regular (at least monthly) interactions (in person or remote) with the participant.

  4. If potential participant reports use of medications typically prescribed for dementia such as, but not limited to, Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, Aducanumab, Leqembi or Lecanemab, Donanemab, the dose must be stable for at least 12 weeks prior to study enrollment.

  5. Potential participant must demonstrate adequate decisional capacity, in the judgment of the investigator, and capable of to making an informed decision regarding their participation in this research study.

  6. Potential participant must be likely able to complete all study activities and outcome measures in the judgment of the investigator.

  7. Potential participant must have the visual, auditory, and motors capacity to use the computerized intervention in the judgment of the investigator.

  8. Potential participant must be able to communicate in either English or French.

Exclusion Criteria:

  1. Potential participant has an existing diagnosis of major neurocognitive disorder at screening (DSM-IV).
  2. Potential participant who answered 'yes' to question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS or 'yes' to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on the C-SSRS "Suicidal Behavior" if the ideation or behavior occurred within 2 months from Participant's date of consent (as recommended by the FDA for treatment trials.)
  3. Potential participant scores >10 on the Geriatric Depression Scale - Short Form (GDS-SF).
  4. Potential participant has previously completed 10 or more hours of the computerized cognitive intervention program manufactured by Posit Science.
  5. Potential participant is participating in a concurrent clinical trial (involving an investigational pharmaceutical, behavioral treatment, medical device or other) that, in the judgment of the investigator, could affect the outcome of this study.
  6. Potential participant is pregnant or breastfeeding.
  7. Potential participant has claustrophobia or implantation with any medical devices above the waist that may concentrate radio frequency fields or have other medical issues that may frustrate participation in MRI/PET imaging procedures.
  8. Potential participant has a history of large vessel stroke with significant residual motor or cognitive impairment.
  9. Potential participant has a history of moderate to severe traumatic brain injury with residual cognitive symptoms.
  10. Potential participant has a history of brain tumor.
  11. Potential participant has a congestive heart failure diagnosis.
  12. Potential participant has a primary diagnosis of idiopathic Parkinson's disease.
  13. Potential participant has multiple sclerosis or Amyotrophic lateral sclerosis diagnosis.
  14. Potential participant has evidence of a non-neurodegenerative neurological disorder that would interfere with the ability to carry out study activities.
  15. Potential participant has has evidence of any other unstable medical conditions that would interfere with the ability to carry out study activities or cause fluctuations in cognition (for example, but not limited to, unstable diabetes, chronic obstructive pulmonary disorder dependent on oxygen).
  16. Potential participant has any other clinically significant or unstable medical condition (for example, but not limited to, ongoing alcohol dependency or drug abuse, schizophrenia, psychosis) that in the investigator's opinion would interfere with the ability to carry out study activities.
  17. Potential participant is undergoing or plans to undergo surgery requiring anesthesia, chemotherapy, or radiation treatment in the six months following screening (can be rescreened and enrolled later).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Speed Training

Computerized speed-based cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.

Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.

有源比较器:Executive Function Training

Computerized executive function cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.

Thirty minutes of training on computerized exercises that target executive function.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Global cholinergic signaling using [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET)
大体时间:at 3 months (post-intervention)

FEOBV standard uptake value ratios (SUVR) in the global cortex ROI. Higher score is better.

at 3 months (post-intervention)

其他结果措施

结果测量
措施说明
大体时间
Change in Memory-based cholinergic signaling in hippocampus gyrus using [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET)
大体时间:at 3 months (post-intervention)

FEOBV-PET standard uptake value ratios (SUVR) hippocampus gyrus using Matched MNI-space region via Hammers Atlas. Higher score is better.

at 3 months (post-intervention)
Change in Memory-based cholinergic signaling in parahippocampal gyrus using [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET)
大体时间:at 3 months (post-intervention)

FEOBV-PET standard uptake value ratios (SUVR) parahippocampal gyrus using Matched MNI-space region via Hammers Atlas. Higher score is better

at 3 months (post-intervention)
Change in NIH EXAMINER Executive Composite Score
大体时间:at 3 months (post-intervention) and at 6 months (follow-up)

The NIH EXAMINER is a computer based battery of executive function tests which yields a total or 'composite' score to represent global executive functioning. Higher score is better.

at 3 months (post-intervention) and at 6 months (follow-up)
Change in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score
大体时间:at 3 months (post-intervention) and at 6 months (follow-up)

The Clinical Dementia Rating (CDR) Scale is a validated assessment for evaluating severity of dementia. Lower score is better.

at 3 months (post-intervention) and at 6 months (follow-up)
Change in Double Decision train-to-task Assessment Score
大体时间:at 3 months (post-intervention) and at 6 months (follow-up)

This is a computerized assessment that serves as a positive control for task learning. A single exposure duration (in milliseconds) required for users to achieve approximately 80% criterion accuracy in identification of central and peripheral targets. Higher score is better.

at 3 months (post-intervention) and at 6 months (follow-up)
Change in Eye-tracking Test
大体时间:at 3 months (post-intervention) and at 6 months (follow-up)

Eye movements will be measured to determine acetylcholinergic function over time. A series of oculomotor tasks will be presented sequentially on an iPad Pro for approximately 20 minutes. Each task consists of visual stimuli designed to elicit specific eye movements. The iPad's front-facing camera will record facial and eye movements during task performance.

at 3 months (post-intervention) and at 6 months (follow-up)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Mouna Attarha, PhD、Posit Science Corporation

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月25日

初级完成 (估计的)

2027年5月31日

研究完成 (估计的)

2027年5月31日

研究注册日期

首次提交

2025年11月14日

首先提交符合 QC 标准的

2025年11月19日

首次发布 (实际的)

2025年11月24日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • PSC-0703-25

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅